Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$34.09 USD
-0.56 (-1.62%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $34.06 -0.03 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DYN 34.09 -0.56(-1.62%)
Will DYN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DYN
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy
Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect?
Other News for DYN
Buy Rating on Dyne Therapeutics Backed by Promising Clinical Data and Broad Therapeutic Potential of FORCE Platform
Dyne Therapeutics participates in a conference call with JPMorgan
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
Dyne announces new Pompe disease data showing potential of FORCE platform
Dynagreen Environmental Unveils New Board Structure